Full Text

Turn on search term navigation

© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Brown adipose tissue (BAT) activation stimulates energy expenditure in human adults, which makes it an attractive target to combat obesity and related disorders. Recent studies demonstrated a role for G protein-coupled receptor 120 (GPR120) in BAT thermogenesis. Here, we investigated the therapeutic potential of GPR120 agonism and addressed GPR120-mediated signaling in BAT. We found that activation of GPR120 by the selective agonist TUG-891 acutely increases fat oxidation and reduces body weight and fat mass in C57Bl/6J mice. These effects coincided with decreased brown adipocyte lipid content and increased nutrient uptake by BAT, confirming increased BAT activity. Consistent with these observations, GPR120 deficiency reduced expression of genes involved in nutrient handling in BAT. Stimulation of brown adipocytes in vitro with TUG-891 acutely induced O2 consumption, through GPR120-dependent and GPR120-independent mechanisms. TUG-891 not only stimulated GPR120 signaling resulting in intracellular calcium release, mitochondrial depolarization, and mitochondrial fission, but also activated UCP1. Collectively, these data suggest that activation of brown adipocytes with the GPR120 agonist TUG-891 is a promising strategy to increase lipid combustion and reduce obesity.

Details

Title
The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat
Author
Schilperoort, Maaike 1   VIAFID ORCID Logo  ; van Dam, Andrea D 2 ; Hoeke, Geerte 2 ; Shabalina, Irina G 3   VIAFID ORCID Logo  ; Okolo, Anthony 4 ; Hanyaloglu, Aylin C 4 ; Dib, Lea H 5 ; Mol, Isabel M 2 ; Caengprasath, Natarin 4 ; Yi-Wah, Chan 6 ; Damak, Sami 7 ; Anne Reifel Miller 8 ; Coskun, Tamer 8 ; Shimpukade, Bharat 9 ; Ulven, Trond 9 ; Kooijman, Sander 2 ; Patrick CN Rensen 2 ; Christian, Mark 10   VIAFID ORCID Logo 

 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK; Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden, The Netherlands 
 Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden, The Netherlands 
 Department of Molecular Biosciences, The Wenner-Gren Institute, The Arrhenius Laboratories F3, Stockholm University, Stockholm, Sweden 
 Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, London, UK 
 Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK 
 Lymphocyte Development Group, MRC London Institute of Medical Sciences, Hammersmith Campus, Imperial College London, London, UK 
 Nestlé Research Center, Lausanne, Switzerland 
 Lilly Research Laboratories, Diabetes/Endocrine Department, Lilly Corporate Center, Indianapolis, IN, USA 
 Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark 
10  Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK 
Section
Research Articles
Publication year
2018
Publication date
Mar 2018
Publisher
EMBO Press
ISSN
17574676
e-ISSN
17574684
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2011202702
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.